Cushing's Disease
Older adults with Cushing’s disease present with fewer symptoms than younger patients
The presentation of Cushing’s disease varies by age, with older adults having fewer hallmark features of the condition and more comorbidities, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.
VIDEO: Data shed new light on treatments for acromegaly, Cushing’s disease
BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.
Osilodrostat improves comorbid hypertension, diabetes for adults with Cushing’s disease
BOSTON — Long-term osilodrostat therapy may improve symptoms of comorbid cardiometabolic disorders such as hypertension and diabetes for adults with Cushing’s disease, according to data presented at ENDO 2024.
Top in endocrinology: FDA warns about noninvasive glucose readings; diabetes in children
The FDA issued a warning to people with diabetes not to use smartwatches or smart rings that do not pierce the skin for measuring blood glucose because the readings could be inaccurate.
Surgical remission of Cushing’s disease may increase odds for autoimmune disease
Adults who achieved remission after surgery for Cushing’s disease are more likely to develop autoimmune disease than those with nonfunctioning pituitary adenomas, according to data published in Annals of Internal Medicine.
CATALYST: Hypercortisolism prevalence high with difficult-to-treat type 2 diabetes
Hypercortisolism is prevalent among nearly one-quarter of people with difficult-to-control type 2 diabetes enrolled in a prospective phase 4 study, according to an industry press release.
Most adults with Cushing’s disease achieve remission with ketoconazole after surgery
Most adults with Cushing’s disease who received ketoconazole after transsphenoidal surgery had a reduction in cortisol to normal levels, according to findings published in Frontiers in Endocrinology.
A coming ‘renaissance in endocrinology’: A conversation with R. Scott Struthers, PhD
R. Scott Struthers, PhD, had a lab job synthesizing peptide hormones as a college freshman. That experience launched a career featuring discovery of novel agents for endocrine diseases, women’s health conditions and cancers.
Osilodrostat normalizes urinary free cortisol in Cushing’s disease for most at 72 weeks
More than 80% of adults with Cushing’s disease receiving osilodrostat had normalized mean urinary free cortisol levels at 72 weeks of treatment, according to findings from the LINC 3 study extension.
Osilodrostat normalizes urinary free cortisol in most adults with Cushing’s disease
More than three-quarters of adults with Cushing’s disease assigned osilodrostat had a normalized mean urinary free cortisol level at 12 weeks and maintained a normal level at 36 weeks, according to data from the LINC 4 phase 3 trial.